A new test meant to diagnose Alzheimer's disease is almost ready to be distributed commercially. This new method uses a biochemical diagnosis to evaluate whether a patient is developing the condition, which was previously only possible through the analysis of brain tissue.
"Our clinical study shows that a non-invasive blood test, based on a biochemical process, may be successfully used to diagnose Alzheimer's at an early stage and differentiate it from other types of dementia," said study author Dr. Vassilios Papadopoulos.
He added that the diagnosis could now be possible in the very early stages of the disease. This could potentially give families time to plan for the safety of a patient. Many may choose to install a senior alert system in an older adult's home, because this device can be used to instantly send a medical alert if assistance is required.
The Alzheimer's Association has especially outlined the impact that the condition will have on the baby boomer generation, estimating that one out of every eight boomers will develop the illness. Currently, 5.4 million Americans suffer from Alzheimer's disease and 14.9 million unpaid caregivers watch over them.